Novartis Pharma AG, Basel, Switzerland.
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
J Eur Acad Dermatol Venereol. 2018 Feb;32(2):282-290. doi: 10.1111/jdv.14584. Epub 2017 Oct 12.
Quantification of burden of chronic spontaneous urticaria (CSU) vs. psoriasis (PsO) is limited.
To evaluate the burden associated with CSU vs. PsO of all severities (overall PsO), mild and moderate/severe PsO.
This retrospective cross-sectional analysis compared data from adult patients with chronic urticaria (CU), used as a proxy for CSU, and PsO from the National Health and Wellness Survey in France, Germany, Italy, Spain and the United Kingdom. Outcomes included mental and physical component summary scores (MCS and PCS) calculated from the Short Form (SF)-36v2 or SF-12v2, SF-6D health utility scores, self-reported psychological complaints (anxiety, depression and sleep difficulties), work productivity and activity impairment, and self-reported healthcare resource utilization. Bivariate and multivariate analyses for each outcome and comparative groups were conducted.
This analysis included 769 CU and 7857 PsO (26.9% moderate/severe) patients. Following adjustment for covariates, CU patients showed a greater health-related quality of life (HRQoL) impairment vs. overall PsO (MCS: -2.4, PCS: -1.6, SF-6D: -0.03; all P < 0.001). CU patients showed a higher risk of anxiety, depression and sleep difficulties [odds ratio (OR): 1.63, 1.34 and 1.56, respectively; all P < 0.01] and greater healthcare resource use vs. overall PsO. The overall activity impairment was significantly greater in CU patients than in overall PsO patients (P = 0.001), while the impact on work was not significantly different. The results vs. moderate/severe PsO group showed no significant differences on all outcomes.
Burden of illness in CU is higher than PsO of all severities but similar to that observed in moderate/severe PsO. Both diseases have a similar negative impact on work productivity.
慢性自发性荨麻疹（CSU）与银屑病（PsO）负担的量化有限。
评估所有严重程度（总体 PsO）、轻度和中重度/重度 PsO 的 CSU 与 PsO 相关的负担。
本回顾性横断面分析比较了来自法国、德国、意大利、西班牙和英国的国家健康和健康调查的慢性荨麻疹（CU）成年患者数据，CU 用作 CSU 的替代指标。结果包括使用 SF-36v2 或 SF-12v2 计算的心理和生理成分综合评分（MCS 和 PCS）、SF-6D 健康效用评分、自我报告的心理困扰（焦虑、抑郁和睡眠困难）、工作生产力和活动障碍，以及自我报告的医疗资源利用情况。对每个结果和比较组进行了双变量和多变量分析。
本分析纳入了 769 例 CU 和 7857 例 PsO（26.9%为中重度/重度）患者。调整协变量后，CU 患者的健康相关生活质量（HRQoL）损害大于总体 PsO（MCS：-2.4，PCS：-1.6，SF-6D：-0.03；均 P<0.001）。CU 患者出现焦虑、抑郁和睡眠困难的风险更高[比值比（OR）：1.63、1.34 和 1.56；均 P<0.01]，并且比总体 PsO 患者需要更多的医疗保健资源。CU 患者的总体活动障碍明显大于总体 PsO 患者（P=0.001），而对工作的影响则无显著差异。与中重度/重度 PsO 组相比，所有结果均无显著差异。
CU 的疾病负担高于所有严重程度的 PsO，但与中重度 PsO 观察到的负担相似。这两种疾病对工作生产力都有类似的负面影响。
